Long-term survival after radical prostatectomy for men with high gleason sum in pathologic specimen

Urology

Volumn 76, Issue 3, 2010, Pages 715-721

  Pierorazio, Phillip M ^a   Guzzo, Thomas J ^a   Han, Misop ^a   Bivalacqua, Trinity J ^a   Epstein, Jonathan I ^a   Schaeffer, Edward M ^a   Schoenberg, Mark ^a   Walsh, Patrick C ^a   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DATA BASE; DISEASE FREE SURVIVAL; EVALUATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SEMINAL VESICLE; TREATMENT OUTCOME; MIDDLE AGED; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649357206     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.11.085     Document Type: Article

References (25)

1. M. Han, A.W. Partin, and C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555 565
2. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
3. M.W. Kattan, J.A. Eastham, and A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
4. M.W. Kattan, T.M. Wheeler, and P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507
5. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114 (Pubitemid 23175983)
6. G.D. Grossfeld, D.M. Latini, and D.P. Lubeck Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer J Urol 169 2003 157 163
7. C.R. Pound, A.W. Partin, and J.I. Epstein Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control Urol Clin North Am 24 1997 395 406
8. W.K. Lau, E.J. Bergstralh, and M.L. Blute Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables J Urol 167 2002 117 122
9. S.E. Schild, W.W. Wong, and G.L. Grado The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer Int J Radiat Oncol Biol Phys 34 1996 535 541
10. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
11. P.J. Bastian, M.L. Gonzalgo, and W.J. Aronson Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10 Cancer 107 2006 1265 1272
12. W.J. Catalona, A.J. Stein, and W.R. Fair Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases J Urol 127 1982 919 922
13. J.I. Epstein, G. Pizov, and P.C. Walsh Correlation of pathologic findings with progression after radical retropubic prostatectomy Cancer 71 1993 3582 3593
14. M. Han, A.W. Partin, and S. Piantadosi Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer J Urol 166 2001 416 419
15. M.V. Tefilli, E.L. Gheiler, and R. Tiguert Role of radical prostatectomy in patients with prostate cancer of high Gleason score Prostate 39 1999 60 66
16. G.S. Gerber, R.A. Thisted, and P.T. Scardino Results of radical prostatectomy in men with clinically localized prostate cancer JAMA 276 1996 615 619
17. H. Zincke, J.E. Oesterling, and M.L. Blute Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer J Urol 152 1994 1850 1857
18. G.W. Chodak, R.A. Thisted, and G.S. Gerber Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
19. A.W. Partin, B.R. Lee, and M. Carmichael Radical prostatectomy for high grade disease: a reevaluation 1994 J Urol 151 1994 1583 1586
20. A.W. Partin, H.B. Carter, and D.W. Chan Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia J Urol 143 1990 747 752
21. S.A. Boorjian, R.J. Karnes, and L.J. Rangel Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers BJU Int 101 2008 299 304
22. T.H. Van der Kwast, M. Bolla, and H. Van Poppel Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911 J Clin Oncol 25 2007 4178 4186
23. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
24. D.A. Loblaw, K.S. Virgo, and R. Nam Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605
25. P.C. Walsh Urological oncology: prostate cancer: editorial comment on intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group J Urol 182 2009 2728